Core Viewpoint - Banco Santander is streamlining operations and focusing on high-growth markets in Europe and the Americas, highlighted by the sale of a 49% stake in its Polish banking business for €6.8 billion ($7.7 billion) [1][2]. Group 1: Transaction Details - Banco Santander sold approximately 49% of Santander Bank Polska to Erste Group for €6.8 billion, with an additional acquisition of 50% of the asset management business for €0.2 billion, totaling €7 billion [1][2]. - The transaction is expected to close by year-end and will result in a €2 billion net capital gain for Banco Santander [2]. - Post-transaction, Banco Santander will retain around 13% of Santander Polska and plans to acquire the remaining 60% of Santander Consumer Bank Polska [3]. Group 2: Financial Impact - Following the transaction, Banco Santander will temporarily have a CET1 ratio above its target of 12-13%, with plans to return to this range by strategically deploying capital [4]. - The bank intends to distribute 50% of the released capital, approximately €3.2 billion, through share buybacks, contributing to its €10 billion buyback target for 2025-2026 [4]. - The transaction is projected to be accretive to earnings by 2027-2028, supporting further growth through share buybacks and strategic acquisitions [5]. Group 3: Digital Expansion and Transformation - Banco Santander plans to close about 20 U.S. branches, approximately 5% of its U.S. retail network, to streamline operations and adapt to digital banking trends [9]. - The U.S.-based digital platform, Openbank, has surpassed $2 billion in deposits since its launch in October 2024, becoming Europe's largest fully digital bank by deposit volume [10][11]. - The One Transformation program, initiated in 2014, focuses on digital transformation and operational efficiency, contributing to a strong first-quarter 2025 net profit of €3.4 billion, marking a 19% year-over-year growth [12][13]. Group 4: Analyst Sentiments and Market Performance - The Zacks Consensus Estimate indicates a 3.6% decline in revenues for 2025, but a 3.4% growth is expected in 2026, with earnings projected to increase by 12.1% and 12.2% for 2025 and 2026, respectively [18]. - Banco Santander's shares have risen 62.3% year-to-date, outperforming the industry average of 16.1% [20]. - The current trading valuation of Banco Santander at 1.25X P/TB is below the industry average of 2.18X, indicating it is relatively inexpensive compared to peers [24][28].

I recommend holding Santander Brasil (NYSE: BSBR ) shares after the release of its Q1 2025 results. This article is a continuation of my initial coverage article published on May 6, 2024, with a sell recommendation at the time.More than 5 years of experience in equity analysis in LatAm. We provide our clients with in-depth research and insights to help them make informed investment decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, an ...

Group 1: Santander's Sale and Partnership - Santander is selling approximately 49% of Santander Polska's share capital and 50% of its Polish asset management business to Erste Group for $7.9 billion [1][2] - The deal includes a partnership where Santander will provide Erste access to its payment system, allowing both banks to explore opportunities in payments, particularly with Santander Polska post-completion [1][2] Group 2: Corporate and Investment Banking Collaboration - Santander and Erste are forming a corporate and investment banking partnership to leverage each other's regional strengths, offering local solutions and market insights to corporate and institutional clients through a referral model [3] - This partnership aims to facilitate seamless client interactions and service offerings [3] Group 3: Economic Outlook and Strategic Focus - Santander's Executive Chair, Ana Botín, highlighted the bank's focus on helping clients manage volatility related to U.S. tariffs and geopolitical uncertainty, which has contributed to a decline in the five-year growth forecast for the world economy to 3.1%, the lowest in 16 years [4] - The bank is leveraging its global scale and diversification as stabilizers in the current economic environment, anticipating continued profitability growth by 2025 [5] Group 4: Importance of Real-Time Payments - Research indicates that offering real-time payments is crucial for banks to attract and retain small and medium-sized business (SMB) clients, with many SMBs willing to pay fees for instant payment advantages [6][7] - Specifically, 88% of the smallest SMBs, those with annual revenues of less than $100,000, would be willing to pay a percentage fee for instant payments [7]

Core Points - The document provides information regarding the total number of voting rights and shares of Sanofi as of March 31, 2025 [1] - Sanofi has a registered share capital of €2,452,461,656 and is registered at the Paris Commercial and Companies Registry [1] Summary by Category Voting Rights and Shares - Total number of issued shares as of March 31, 2025, is 1,233,737,221 [1] - The number of real voting rights, excluding treasury shares, is 1,351,370,330 [1] - The theoretical number of voting rights, including treasury shares, is 1,366,610,643 [1]

After underperforming for so long, it is nice to see Banco Santander, S.A. ( NYSE: SAN ) doing much better these days. Even by the standards of European financials, this bank has been an exceptional performer so far this year, returning over 60% in dollarI like to take a long term, buy-and-hold approach to investing, with a bias toward stocks that can sustainably post high quality earnings. Mostly found in the dividend and income section. Blog about various US/Canadian stocks at 'The Compound Investor', and ...

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The Genera ...

Company Overview - Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to CD&R, while retaining a 48.2% stake [1] - The transaction generated approximately €10 billion in net cash proceeds for Sanofi [1] Opella's Position and Strategy - Opella is now an independent global leader in consumer healthcare, positioned for long-term success with a strong brand portfolio and international reach [3][5] - The company employs over 11,000 people and operates in 100 countries, with 13 manufacturing sites and four development centers [5] - Opella is the third-largest player in the OTC and vitamins, minerals & supplements market, serving over half a billion consumers globally [5] Future Outlook - CD&R aims to support Opella in becoming a global consumer health champion, leveraging its expertise in the consumer health sector [4] - Opella is focused on unlocking its full potential and driving value creation through innovation and exceptional talent [5]

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April, 2025 Commission File Number: 001-12518 Banco Santander, S.A. (Exact name of registrant as specified in its charter) Ciudad Grupo Santander 28660 Boadilla del Monte (Madrid) Spain (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F ...

Core Points - Sanofi has expanded its partnership with McLaren Racing and United Autosports to raise awareness about meningitis during the 24 Hours of Le Mans race [2][3] - The Meningitis Flag will be prominently displayed on the 59 McLaren car and worn by team drivers, aiming to increase global awareness of meningitis [2][3][5] - The initiative highlights the importance of vaccination, early detection, and symptom awareness in combating meningitis, especially in light of rising cases post-COVID-19 pandemic [3][5] Company and Industry Insights - Every 15 seconds, someone contracts meningitis, with bacterial meningitis being particularly severe and potentially fatal within 24 hours [3] - The partnership between Sanofi and McLaren Racing began in 2022, leveraging McLaren's digital and analytical expertise to enhance Sanofi's manufacturing operations [8] - The Le Mans race attracts over 300,000 attendees and has more than 140 million viewers, providing a significant platform for raising awareness [8]

Core Insights - The company reported a Q1 sales growth of 9.7% at constant exchange rates (CER) and a business EPS of €1.79, indicating a strong start to 2025 [1][3][8] Sales Performance - Pharma launches generated sales of €0.8 billion, reflecting a 43.8% increase, primarily driven by ALTUVIIIO [6] - Dupixent sales reached €3.5 billion, up 20.3%, while vaccine sales amounted to €1.3 billion, up 11.4% due to favorable phasing of Beyfortus [6] - Total IFRS net sales were reported at €9,895 million, representing a 10.8% increase [8] Financial Metrics - Business EPS increased by 17.0% reported and 15.7% at CER, reaching €1.79 [6][8] - IFRS net income rose by 65.2% to €1,872 million, with IFRS EPS reported at €1.52, up 67.0% [8] - Free cash flow was reported at €1,029 million [8] Pipeline and Approvals - The company achieved six regulatory approvals across various therapeutic areas, including immunology, rare diseases, and oncology [6][5] - Significant progress was noted in the pipeline, with new data from mid-stage studies unlocking late-stage studies in asthma and skin diseases [6][5] Capital Allocation and Strategy - The company confirmed its capital allocation strategy, including a share buyback program of €5 billion, with 72% already repurchased [7][4] - The anticipated closing of the sale of a controlling stake in Opella is expected in Q2 [7] Future Outlook - Sales are projected to grow by a mid-to-high single-digit percentage at CER in 2025, with business EPS expected to increase at a low double-digit percentage at CER before share buyback [7]